Free Trial

Bio-Techne (TECH) Stock Price, News & Analysis

Bio-Techne logo
$52.59 -0.09 (-0.17%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$51.81 -0.78 (-1.48%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bio-Techne Stock (NASDAQ:TECH)

Key Stats

Today's Range
$51.83
$53.61
50-Day Range
$46.66
$53.90
52-Week Range
$46.01
$83.62
Volume
1.51 million shs
Average Volume
1.46 million shs
Market Capitalization
$8.24 billion
P/E Ratio
64.13
Dividend Yield
0.61%
Price Target
$71.36
Consensus Rating
Moderate Buy

Company Overview

Bio-Techne Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
99th Percentile Overall Score

TECH MarketRank™: 

Bio-Techne scored higher than 99% of companies evaluated by MarketBeat, and ranked 16th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bio-Techne has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Bio-Techne has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bio-Techne's stock forecast and price target.
  • Earnings Growth

    Earnings for Bio-Techne are expected to grow by 17.96% in the coming year, from $1.67 to $1.97 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bio-Techne is 64.13, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.91.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bio-Techne is 64.13, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.00.

  • Price to Earnings Growth Ratio

    Bio-Techne has a PEG Ratio of 2.50. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Bio-Techne has a P/B Ratio of 4.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Bio-Techne's valuation and earnings.
  • Percentage of Shares Shorted

    4.08% of the float of Bio-Techne has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Techne has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Techne has recently decreased by 18.57%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Bio-Techne has a dividend yield of 0.61%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Bio-Techne does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Bio-Techne is 39.02%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 16.24% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

  • Read more about Bio-Techne's dividend.
  • Percentage of Shares Shorted

    4.08% of the float of Bio-Techne has been sold short.
  • Short Interest Ratio / Days to Cover

    Bio-Techne has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bio-Techne has recently decreased by 18.57%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Bio-Techne has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Bio-Techne this week, compared to 11 articles on an average week.
  • Search Interest

    Only 4 people have searched for TECH on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bio-Techne insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.90% of the stock of Bio-Techne is held by insiders.

  • Percentage Held by Institutions

    98.95% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bio-Techne's insider trading history.
Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Stock News Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Is Bio-Techne Stock Underperforming the Nasdaq?
See More Headlines

TECH Stock Analysis - Frequently Asked Questions

Bio-Techne's stock was trading at $72.03 at the beginning of 2025. Since then, TECH shares have decreased by 27.0% and is now trading at $52.59.

Bio-Techne Corp (NASDAQ:TECH) issued its earnings results on Wednesday, May, 7th. The biotechnology company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of $0.51 by $0.05. Bio-Techne's revenue for the quarter was up 4.2% compared to the same quarter last year.
Read the conference call transcript
.

Shares of Bio-Techne split on the morning of Wednesday, November 30th 2022.The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were distributed to shareholders after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

Bio-Techne's board approved a stock repurchase program on Wednesday, May 7th 2025, which permits the company to buy back $500,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 6.5% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board believes its stock is undervalued.

Bio-Techne subsidiaries include MoGen Biotechnologies, Exosome Diagnostics, Quad Technologies, Advanced Cell Diagnostics, Space Import-Export Srl, Zephyrus Biosciences, Cliniqa, and more.

Top institutional shareholders of Bio-Techne include Rowlandmiller & PARTNERS.ADV (0.03%), Czech National Bank (0.02%), Kera Capital Partners Inc. and Central Pacific Bank Trust Division. Insiders that own company stock include Roeland Nusse, Kim Kelderman, Brenda S Furlow, John L Higgins and Amy E Herr.
View institutional ownership trends
.

Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bio-Techne investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Netflix (NFLX).

Company Calendar

Last Earnings
5/07/2025
Record date for 5/30 Dividend
5/19/2025
Ex-Dividend for 5/30 Dividend
5/19/2025
Dividend Payable
5/30/2025
Today
7/09/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
6/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:TECH
CIK
842023
Employees
3,100
Year Founded
1981

Price Target and Rating

High Price Target
$90.00
Low Price Target
$59.00
Potential Upside/Downside
+35.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Trailing P/E Ratio
64.13
Forward P/E Ratio
31.49
P/E Growth
2.5
Net Income
$168.10 million
Pretax Margin
13.48%

Debt

Sales & Book Value

Annual Sales
$1.16 billion
Cash Flow
$2.31 per share
Price / Cash Flow
22.77
Book Value
$13.13 per share
Price / Book
4.01

Miscellaneous

Free Float
150,653,000
Market Cap
$8.24 billion
Optionable
Optionable
Beta
1.39

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:TECH) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners